



DRUG DISCOVERY

# Integrated degrader platform



## Our integrated degrader platform

**With decades of expertise in the fields of biological research and drug discovery, Nuvisan provides a fully integrated protein degradation platform encompassing a full range of PROTAC/molecular glue drug discovery services, utilising cutting-edge technologies.**

Our services span both chemistry and biology to align with your novel drug discovery goals. We offer packages that include a variety of tailored services covering the entire drug discovery process.

We offer integrated solutions to take your degrader molecule from target validation to investigational new drug (IND).

Our design and highly efficient synthesis platform, combined with high-quality in vitro assays, offers a quick turnaround time, enabling informed decisions to advance your degrader discovery program.

We offer over 100 diverse in vivo models across various therapeutic areas, such as oncology, inflammation, CNS disorders, dermatology, metabolic diseases, and female health, to support pharmacokinetics-pharmacodynamics (PK/PD) and efficacy studies.



# Integrated degrader platform



## EXPERTISE

Nuvisan offers comprehensive capabilities for drug discovery involving degraders like PROTACs and molecular glues. Key features include a robust degrader library containing over 20 ligands for E3 ligases, 7,000 linkers, and 100 precursors, enabling the design of targeted molecules.

The platform offers “direct-to-biology” (D2B) workflows for producing over 100 degraders per day, along with a 3-million-compound library supported by 1 billion in vitro and in vivo data points. Nuvisan emphasises end-to-end degrader packages, from chemistry to biological insights, and boasts a team of over 50 scientists and lab professionals with extensive expertise in integrated drug discovery.

Additional strengths include state-of-the-art biochemical and cell-based assays, AAALAC-accredited in vitro and in vivo models, and advanced tools for degrader screening. This comprehensive suite is tailored for efficient and innovative drug development.



# Hit degrader identification to in vivo proof-of-concept



## LIFE SCIENCE CHEMISTRY

We offer innovative strategies for the rapid discovery of PROTACs and molecular glues across all business models, including consulting, degrader design, fast library synthesis, and integrated projects from conception to success.


- In silico tools supported PROTACs and glues design
- Ready-to-use collection of linkers and E3 binders
- Fast synthesis and direct-to-biology
- Multi-parameter optimisation



## DISCOVERY BIOSCIENCES

Our platform encompasses all assay formats for cell-free and cell-based assays, covering target engagement, ternary complex formation, target degradation, and mode-of-action analysis.

- Biochemical: ASMS, SPR, TSA, X-Ray, HTRF and NanoBRET
- Cell-based: HCA, HiBiT (CRISPR KI or OE), NanoBRET, AlphaLISA, Western Blot, ProteinSimple
- Proteomics for selectivity of degradation
- Customer-specific assays/assay development services





# NUVISAN



## IN VIVO PHARMACOLOGY

Integrated pharmacology services covering the entire drug discovery and development chain. We have various in vivo models available for different therapeutic areas to support:

- Efficacy studies
- Exposure studies
- Biomarker studies correlating PK/PD relationship
- Formulation approaches to ensure bioavailability of compounds




## DMPK (DRUG METABOLISM AND PHARMACOKINETICS)

Our DMPK discovery bioanalysis services can support the stages of drug discovery, from lead confirmation and lead optimisation to preclinical studies. We offer a comprehensive range of services:

- Pharmacokinetic (PK) and pharmacodynamic (PD) analysis
- Toxicokinetic analysis
- High-quality PK/PD assessments with industry-standard PK/PD analysis tools



FOLLOW US



# THE SCIENCE CRO

YOUR PARTNER OF  
CHOICE IN BRINGING  
THERAPEUTICS TO LIFE


**Nuvisan is a full-service contract research organisation (CRO) and development and manufacturing organisation (CDMO) with state-of-the-art laboratories in Germany and France.**

Our pharmaceutical, biotechnology, venture capital and non-profit clients partner with us because our high-quality end-to-end solutions and scientific expertise enable us to streamline and accelerate drug discovery and development – from ensuring target understanding to helping bring therapeutics to life.

Founded over 40 years ago by a team of pharma industry innovators, Nuvisan has established a reputation for expertise and professionalism.

Our team leaders have extensive experience in the biopharma industry, and our unique centres of excellence – for drug discovery in Berlin, formulation and GMP manufacturing in Sophia Antipolis, and our bioanalysis hub in Neu-Ulm – enable our experienced scientists to help guide and advance projects.

We know how to discover, develop and bring the next generation of medicines to market. At the same time, we are committed to flexibility, transparency and collaboration in our approach, working closely with you to adapt to your individual needs, minimise risks and help deliver your project.



## Contact us

**NUVISAN**

Nuvisan ICB GmbH  
Muellerstrasse 178  
13353 Berlin  
Germany

hello@nuvisan.com  
+49 731 9840 - 0

[nuvisan.com](https://www.nuvisan.com)